SUSANNAH MARIE HALL APRN
Prescription History 1922545136
Nurse Practitioner in Tampa, FL

NPI Status: Active since January 25, 2017

Contact Information

110 CHESAPEAKE AVE
TAMPA, FL
ZIP 33606
Phone: (813) 344-7418

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for SUSANNAH MARIE HALL APRN, an active Nurse Practitioner specialist practicing in Tampa, FL. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 58 documented patient claims. Among these therapy options, the most frequently utilized medication is Lagevrio (Eua), which accounts for 42 claims alone.

Medication Index

No matching medications currently found on file.

Lagevrio (Eua)

Generic Formulation: MolnupiravirSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 42
30-Day Fills 42.0
Days Supply 210
FL State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.9
Peer Average Days Supply120
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 82.6% higher than the standard regional baseline profile for FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $417.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.94

State Avg Cost Per Claim

$10.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Molnupiravir is a product that the FDA is allowing to be given for emergency use to treat COVID-19. It is used by adults 18 years of age and older who have recently tested positive for coronavirus, have had mild to moderate symptoms for no more than 5 days and are not hospitalized. To receive this product you must also be at high risk for COVID-19 complications due to older age, obesity, or ongoing medical conditions (such as lung or heart disease or diabetes, among others). Talk to your doctor about the risks and benefits of treatment with molnupiravir. Molnupiravir works by preventing the growth of the virus that causes COVID-19. More information about molnupiravir is available from the FDA Fact Sheet for Patients, Parents, and Caregivers for Emergency Use. There is limited information about how safe and effective molnupiravir is for treating COVID-19. Study results show that molnupiravir may help people who have recently tested positive for coronavirus stay out of the hospital. This product is not for use by people who are hospitalized due to COVID-19. The information in this document reflects emerging data, which is evolving and subject to reassessment. Users should be aware of these considerations in their review of molnupiravir, and it is always the responsibility of treating practitioners to exercise independent judgement in making care decisions.

Ondansetron Odt

Generic Formulation: OndansetronSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 77
FL State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills24.8
Peer Average Days Supply345
Conservative Utilization

This provider writes prescriptions for this formulation 30.4% less frequently than the standard regional baseline metric for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $118.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.39

State Avg Cost Per Claim

$28.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. Ondansetron works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like SUSANNAH MARIE HALL APRN provides transparency into local medical care patterns within Tampa, FL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Nurse Practitioner** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.